অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - fluoxetine hydrochloride, quantity: 4.47 mg/ml (equivalent: fluoxetine, qty 4 mg/ml) - oral liquid - excipient ingredients: glycerol; purified water; benzoic acid; sucrose; flavour - the treatment of major depressive disorders as defined in the approved product information. the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (ocd), as defined in the dsm-iii-r; ie. the obsessions and compulsions cause marked distress, are time consuming, or significantly interfere with social or occupational functioning. indications as at 6 june 2000: for the treatment of: major depression. obsessive compulsive disorders. premenstrual dysphoric disorder (pmdd) as defined by dsm-iv criteria. the essential features of pmdd, according to the diagnostic and statistical manual-4th edition (dsm-iv) include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating a

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; benzoic acid; purified water; hydrochloric acid - rixadone is indicated for the treatment of schizophrenia and related psychoses.,rixadone is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,rixadone is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,rixadone is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,rixadone is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - riluzole, quantity: 0.5 g - oral liquid, suspension - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); aluminium magnesium silicate; xanthan gum; saccharin sodium; sodium lauryl sulfate; ceteareth-25; purified water; sodium chloride; dimeticone 100; benzoic acid; sorbic acid; methylcellulose; polysorbate 65; glyceryl distearate; silicon dioxide; dimeticonol; peg-4 stearate - riluzole is indicated for the treatment of patients with amyotrophic lateral sclerosis (als).

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - magnesium hydroxide, quantity: 24 mg/ml; aluminium hydroxide, quantity: 50 mg/ml; magnesium trisilicate, quantity: 24 mg/ml - oral liquid, suspension - excipient ingredients: hymetellose; sodium hydroxide; propyl hydroxybenzoate; glycerol; purified water; hydrogen peroxide; saccharin sodium; peppermint oil; ethanol; vanillin; ethyl hydroxybenzoate; sodium hypochlorite - fast, effective and long lasting relief from: indigestion, heartburn, upset stomach.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - cannabidiol, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: sesame oil; sucralose; ethanol absolute; flavour - epidyolex is indicated for use as adjunctive therapy of seizures associated with lennox-gastaut syndrome (lgs) or dravet syndrome (ds) for patients 2 years of age and older.

যুক্তরাজ্য - ইংরেজি - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - sirolimus - oral solution - 1mg/1ml

মাল্টা - ইংরেজি - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - pseudoephedrine hydrochloride, triprolidine hydrochloride - oral solution - pseudoephedrine hydrochloride 30 mg triprolidine hydrochloride 1.25 mg - nasal preparations

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - atenolol, quantity: 5 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; propyl hydroxybenzoate; saccharin sodium; purified water; citric acid monohydrate; sorbitol solution (70 per cent) (non-crystallising); sodium citrate dihydrate; methyl hydroxybenzoate; flavour - all grades of hypertension including hypertension of renal origin.,frequent disabling angina without evidence of cardiac failure,cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those with acute myocardial infarction),myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: purified water; sorbitol solution (70 per cent) (non-crystallising); sodium methyl hydroxybenzoate; citric acid; brilliant scarlet 4r; hyetellose; sodium propyl hydroxybenzoate; saccharin sodium; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 20 mg/ml - oral liquid - excipient ingredients: agar; sucrose; methyl hydroxybenzoate; propyl hydroxybenzoate; potassium sorbate; saccharin; polysorbate 80; diethanolamine; purified water; sodium metabisulfite; fragrance (perfume) - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.